Grants and Contributions

To accelerate domestic & international sales by increasing demand through proper marketing and in store sales techniques, while nurturing growing co-packing velocities and introducing a new SKU and eco-friendly packaging.

The FacePass R&D project will build on Face4's recent seamless travel R&D projects with Canada Border Services Agency (air and land borders) and Eurostar (UK Train border). Each of these systems allows a traveller to self-enroll using a mobile app, create a digital travel credential (DTC), and use only face as the single security token for identity verification at the border checkpoint.

The objective project is to develop a more advanced and robust seamless travel solution and pilot it at one of the most secure and demanding airport environments in the world. The input and feedback from Israel Airports Authority will enhance data security, cybersecurity, privacy and traveller/staff user experience for both air and land borders.

The purpose of this CanExport Innovation agreement is to support Canadian organizations to carry out activities related to pursuing opportunities that would lead to establishing new collaborative Research and Development (R&D) partnerships between the Recipient and foreign organizations in order to support R&D on the Recipient’s technology and advance its commercialization.

The purpose of this CanExport Innovation agreement is to support Canadian organizations to carry out activities related to pursuing opportunities that would lead to establishing new collaborative Research and Development (R&D) partnerships between the Recipient and foreign organizations in order to support R&D on the Recipient’s technology and advance its commercialization.

This project is to expand supported devices to allow remote monitoring of patient with different disease states and modernize the architecture of the Panorama-360 platform to make it more scalable for significantly higher volume and for its deployment in other provinces/jurisdictions.

Identify and develop antibody therapeutics for response and preparedness against COVID-19, and expand capacity for rapid development and delivery of antibody therapeutics.

The proposed project will focus on business development activities that will support the successful launch of the firm's diagnostic software tool..

The project targets the prevention of acute organ inflammation injury in the lungs and kidneys of patients who have moderate to severe COVID-19 and other diseases. LSALT peptide is a novel drug candidate and selective dipeptidase-1 inhibitor which blocks injury in the lungs and kidneys by reducing leukocyte recruitment and inflammation in these organs.

This project focuses on completing the clinical and commercial drug development tasks needed to obtain regulatory approval for LSALT peptide. A successful project will advance the LSALT peptide as a new therapeutic that will reduce organ inflammation complications in high risk patients, increase survival rates and provide resiliency in the Canadian healthcare system for future pandemics.

Project to evaluate and quantify whether the addition of microbial consortia to lagoons promotes sludge digestion and water treatment performance.

Poor prescription adherence is a cause in —50% of hospital admissions, causing annual deaths of —125 000 and over $100 billion in annual costs to the healthcare industry1. This project will investigate new technologies to monitor and aid adherence to prescribed medication plans, in order to enable seniors to live longer, healthier and more independent lives. The project will be split into two concurrent work streams (WS). The first WS will focus on development of next generation smart blister packaging. This project builds on almost a decade of expertise in smart packaging at Jones Healthcare Group (JHG), much of which was gained during the Printable Electronics Flagship Program in collaboration with NRC. In particular, JHG now have significant experience in the manufacture, distribution and testing of smart blister packaging, based on a multiple trials performed in recent years. This WS aims to improve manufacturability and add further functionality to smart blister packaging in order to promote adherence and enhance accessibility. The second WS will look at other technologies to aid medication adherence. This will include technologies to monitor liquid medication, as well as methods to monitor other pharmaceutical dispensing technologies. These technologies will enable older adults to live independent lives for longer by improving medication efficiency, reducing hospital admissions, and reassuring family and friends.